Santacruzamate A

Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: Highly potent and selective HDAC2 inhibitor
Chemical Name: Ethyl N-[4-oxo-4-[(2-phenylethyl)amino]butyl]carbamate
Purity: ≥98% (HPLC)
Citations (1)
Literature (4)

Biological Activity for Santacruzamate A

Santacruzamate A is a highly potent and selective histone deactylase 2 (HDAC2) inhibitor (IC50 = 112 - 119 pM). Also inhibits HDAC6 in nanomolar range (IC50 = 433 nM). Displays >3500 fold selectivity for HDAC2 over HDAC6, and >8500-fold selectivity over HDAC4 (IC50 >1 μM for HDAC4). Inhibits growth of HuT-78 cutaneous T-cell lymphoma cell line. Identified as targeting human host proteins that interact with SARS-CoV-2.

Compound Libraries for Santacruzamate A

Santacruzamate A is also offered as part of the Tocriscreen Epigenetics Library. Find out more about compound libraries available from Tocris.

Technical Data for Santacruzamate A

M. Wt 278.35
Formula C15H22N2O3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1477949-42-0
PubChem ID 72946782

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Santacruzamate A

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 27.84 100

Preparing Stock Solutions for Santacruzamate A

The following data is based on the product molecular weight 278.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.59 mL 17.96 mL 35.93 mL
5 mM 0.72 mL 3.59 mL 7.19 mL
10 mM 0.36 mL 1.8 mL 3.59 mL
50 mM 0.07 mL 0.36 mL 0.72 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for Santacruzamate A

References for Santacruzamate A

References are publications that support the biological activity of the product.

Pavlik et al (2013) Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J.Nat.Prod. 76 2026 PMID: 24164245

Gordon et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 583 459 PMID: 32353859

If you know of a relevant reference for Santacruzamate A, please let us know.

View Related Products by Product Action

View all Class I HDAC Inhibitors

Keywords: Santacruzamate A, Santacruzamate A supplier, CAY10683, CAY, 10683, histone, deacetylase, 2, HDAC2, inhibitors, inhibits, highly, potent, selective, Class, I, HDACs, COVID-19, Coronavirus, 7191, Tocris Bioscience

1 Citation for Santacruzamate A

Citations are publications that use Tocris products. Selected citations for Santacruzamate A include:

Steven L et al (2022) INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury. Nat Commun 13 6037 PMID: 36229429

Do you know of a great paper that uses Santacruzamate A from Tocris? Please let us know.

Reviews for Santacruzamate A

There are currently no reviews for this product. Be the first to review Santacruzamate A and earn rewards!

Have you used Santacruzamate A?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.